Does Rusfertide Royalty Deal And Guidance Upgrade Change The Bull Case For Royalty Pharma (RPRX)?

• Royalty Pharma recently agreed to pay Zealand Pharma US$100,000,000 for rights to future royalties and milestones tied to rusfertide, an experimental polycythemia vera treatment with an FDA decision previously guided for the third quarter of 2026.
• This deal adds a new late-stage, specialty-therapy royalty stream to Royalty Pharma’s portfolio, aligning with its focus on broadening exposure to innovative, high‑value medicines.
• We’ll now examine how acquiring future rusfertide royalties, alongside upgraded financial guidance, may influence Royalty Pharma’s existing investment narrative.

AI is about to change healthcare. These 38 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10b in market cap – there’s still time to get in early.

Royalty Pharma Investment Narrative Recap

To own Royalty Pharma, you need to believe its model of buying diversified drug royalties can keep generating attractive cash flows despite patent cycles, policy pressure, and competition for deals. The rusfertide royalty purchase modestly broadens late stage exposure, but it does not change that the most important near term catalyst remains execution against upgraded 2026 guidance, while key risks still center on the Vertex Alyftrek royalty dispute and portfolio concentration in a few blockbuster assets.

Against this backdrop, the recent 2026 guidance raise, delivered alongside Q2 results showing US$1,304.72 million in first half revenue and US$312.57 million in net income, feels particularly relevant. It underlines management’s confidence that existing royalties and new deployments like rusfertide can support the current outlook, even as competition for high quality royalty streams intensifies and healthcare pricing reforms continue to loom in the background.

Yet, beneath this upgraded outlook, investors still need to be aware of how concentrated royalty streams could magnify the impact if…

Read the full narrative on Royalty Pharma (it’s free!)

Royalty Pharma’s narrative projects $4.3 billion revenue and $3.2 billion earnings by 2029. This requires 20.9% yearly revenue growth and about a $2.4 billion earnings increase from $826.3 million today.

Uncover how Royalty Pharma’s forecasts yield a $59.25 fair value, a 5% downside to its current price.

Exploring Other Perspectives

While consensus focuses on steady growth, the most optimistic analysts see rusfertide like deals fitting a future where revenue reaches about US$4.7 billion and earnings US$3.0 billion, reminding you that views on Royalty Pharma’s potential and its reliance on low cost capital can differ widely and may shift again as this new royalty starts to play out.

Explore 4 other fair value estimates on Royalty Pharma – why the stock might be worth just $59.25!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Want Some Alternatives?

Early movers are already taking notice. See the stocks they’re targeting before they’ve flown the coop:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com